GIGA-564
Advanced Solid Tumors
Phase 1Active
Key Facts
About GigaGen
GigaGen is pioneering a novel class of recombinant polyclonal antibody drugs using its industry-leading single-cell technology platforms. Its pipeline includes a Phase 1 anti-CTLA-4 monoclonal antibody (GIGA-564) for oncology and a Phase 1 recombinant polyclonal (GIGA-2339) for Hepatitis B, alongside significant biodefense contracts. As a Grifols subsidiary, the company combines innovative discovery capabilities with the resources and manufacturing expertise of a global plasma leader, positioning it to advance potent, engineered antibody therapies for complex diseases.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |